Lower-Risk MDS: Where We Are and Where We Are Heading
In this segment, “Lower-Risk MDS: Where We Are and Where We Are Heading”, Guillermo Garcia-Manero, MD, and David Sallman, MD, highlight novel and emerging data on the management of lower-risk MDS.
Much progress has been made in MDS therapeutics, with molecular data enabling a deeper understanding of which patients may have poorer prognosis and benefit from targeted interventions. While transfusion independence remains a treatment goal in lower-risk disease, the role of disease-modifying therapies has yet to be defined in this patient population. The discovery of the link between mutations and comorbidities necessitates further exploration in order to optimize outcomes for these patients.